Navigation Links
Finding the Achilles' heel of cancer
Date:12/10/2009

A never-approved drug developed to prevent the death of nerve cells after a stroke can efficiently kill cancer cells while keeping normal cells healthy and intact, an international team led by a Tel Aviv University researcher is reporting in the journal Breast Cancer Research.

Prof. Malka Cohen-Armon of TAU's Sackler School of Medicine found that the stroke drug a member of a family of phenanthridine derivatives developed by an American drug company worked to kill cancer in mice which had been implanted with human breast cancer cells.

"Not only did the drug kill the cancer, but when we investigated normal cells, we discovered that they'd reacted as though they hadn't come in contact with the drug," says Prof. Cohen-Armon. "This is the result we were hoping for. If human trials go well, we could have an entirely new class of drugs in our hands for the fight against cancer."

Stopping the deadly cycle of cancer cell growth

The immediate results of the study were only one of the promising findings in her research, she notes. The team also discovered a molecular mechanism in the cell cycle that can be arrested only in human cancer cells. This cell cycle arrest, they report, causes the cancer cells to die without affecting normal human cells.

"We've found a molecular triggering mechanism in cancer cells that, when set off, causes the cancer cells to die ― they just stop multiplying and die within 48 to 72 hours. Normal, healthy body cells are only temporarily arrested by the same mechanism ― they overcome this cell cycle arrest within 12 hours and continue to proliferate in the presence of the drug as normal un-treated cells," says Prof. Cohen-Armon. "All the human cancer cells we tested seemed to succumb to this compound."

She adds that, even if this particular drug doesn't reach the market to fight against cancer, an entirely new class of drugs might be built around mechanism the team has revealed.

Different strokes

The stroke drug was initially developed to prevent nerve cell death during inflammation and tissue damage in the brain after stroke. However, in pre-clinical studies, American researchers found that these compounds didn't work as well as they'd hoped. Today they are used only for research purposes in laboratory settings.

"The compound we used," says Prof. Cohen-Armon, "presented no traces of toxicity in mice. With this compound, we were able to show how one of the many molecular mechanisms regulating the cell cycle can be targeted, and the proliferation of cancer cells halted." The team is currently working to identify all the regulatory mechanisms involved in this specific process and hope that, in better understanding the science, they might point the way to a new class of anti-cancer drugs.

Her research team was joined by Asher Kastiel, a Ph.D. student from Prof. Shai Izraeli's team working at the Chaim Sheba Medical Center, and the veterinarian Dr. David Castel. All the experiments conform with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health in the United States.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
3. New MRI finding sheds light on multiple sclerosis disease progressio
4. High and mighty: first common height gene identified by researchers behind obesity gene finding
5. Scientists, physicians present latest findings in personalized cancer treatment and prevention
6. Health psychologists discuss latest research findings
7. Incidental findings found when radiologists take a broader look at renal MRA
8. First significant genetic finding in severe PMS, or PMDD
9. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
10. The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products
11. Key findings for all veterans seen in depression and suicide study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding the Achilles' heel of cancer
(Date:3/22/2017)... ... ... College basketball surges to its peak during the March Madness NCAA tournament, but ... to be foster parents. Through a televised spot, Coach Self is inviting adults to ... abuse, neglect and other family challenges. People who respond to Self’s call to community ...
(Date:3/22/2017)... ... ... HumanHaus is proud to announce the launch of its newest invention on crowdfunding ... invented, but our customers today are busy, energetic, multi-taskers that live in a smarter ... and retired that want to travel. The Sweep&Stand is a self-standing broom ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his cutting edge ... focused on a new protocol for treating pain. Dr. Shoshany is among the first ... the first seminar in the country was hosted at his Integrated Chiropractic Practice. ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Sharon Kleyne is ... more than two decades ago to research evaporation of earth’s and the body’s water ... better health. Also the host of the nationally syndicated radio program, The Sharon Kleyne ...
(Date:3/22/2017)... ... March 22, 2017 , ... The International Association of ... specialists and other medical professionals caring for those suffering from the full spectrum ... iaedp Symposium at the Green Valley Resort in Las Vegas, March 22 - ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse Barceló , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
(Date:3/22/2017)... 22, 2017  Levine Cancer Institute today launched ... designed to address lung cancer diagnosis, treatment and ... The mobile lung unit is the first-of-its-kind to ... treatment interventions through integrated mobile technology, traditional treatment ... barriers and a lack of public transportation are ...
Breaking Medicine Technology: